Product
HH-120
Aliases
HH-120 nasal spray, HH-120 Nasal Spray
8 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Preliminary Efficacy of Inhaled HH-120 Aerosol in Participants With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2022-10-10
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of HH-120 Nasal Spray for Post-exposure Prophylaxis of SARS-CoV-2Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic and Immunogenicity of HH-120 Nasal Spray in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of Inhaled HH-120 Aerosol in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-05-26
Clinical trial
A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in Participants Diagnosed With Asymptomatic or Mild COVID-19Status: Completed, Estimated PCD: 2023-01-03
Clinical trial
An Investigator Initiated Clinical Study To Evaluate the Efficacy and Safety of HH-120 Nasal Spray as Post Exposure Prophylaxis (PEP) Regimen in Adult Close Contacts of Individuals Infected With SARS-CoV-2Status: Completed, Estimated PCD: 2022-12-06
Clinical trial
A Single-Arm Clinical Study Evaluating the Efficacy of Post-Exposure Prophylaxis , Safety, and Tolerability of HH-120 Nasal Spray in Close Contacts of SARS-CoV-2Status: Completed, Estimated PCD: 2023-02-06